Market Cap
$235.3M
PALI
PALISADE BIO, INC.
$1.45 ▲ +1.40%
Prev close $1.43Market cap$235.3M
ConsensusStrong Buy
12-mo target$10.22 (+605.0%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)16 New Institutional Positions9 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PALI right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (94%)
Inst. Holders
50 funds
Inst. Value
$189.0M
Inst. Activity
16 buys / 9 sells
Insider Activity
$250.2K buy / $420.2K sell
Insider Net $
-$170.0K
Social Sentiment
75° Bullish
SEC Reports
8
Price chart 30d -27.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Short Volume: PALI — 78.2% short (1.0M / 1.3M)
Short: 987,074 | Exempt: 100 | TRF Vol: 1,262,663 | Short Ratio: 78.2% | Off-exchange volume (dark p
Aug 19, 2026 Insider
Aug 11, 2026 SEC Finley John David gifted 88,400 shares
CEO, CFO
Palisade Bio reported Q2 2026 results in line with Street consensus (EPS -$0.05 vs -$0.05 est), with no revenue surprise
8-K — Impact 5/10
A small insider cluster at Palisade Bio (PALI) shows mixed activity: Director Baltera purchased ~$191K worth of shares o
CLUSTER — Impact 2/10
Jul 9, 2026 Insider
Jul 8, 2026 SEC Baltera Robert Jr. bought 25,000 shares
Director @ $1.96 ($48.9K)
Insider trading cluster at PALISADE BIO shows CEO/CFO John David Finley selling $303K in open-market shares, while Direc
CLUSTER — Impact 3/10
Jul 8, 2026 Insider
Baltera Robert Jr. bought 20,000 shares
Director @ $1.99 ($39.8K)
Jun 30, 2026 Inst.
AMERIPRISE FINANCIAL INC — ADD
11,081,434 shares ($23.2M)
Analyst ratings buy % +4.4%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
94% rate it Buy or better · 16 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jul 23, 2026 | Oppenheimer | INITIATE | Outperform | 52% |
| Apr 9, 2026 | Wolfe Research | INITIATE | Outperform | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Aug 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Jul 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Jun 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% |
Price targets
Where 9 covering analysts think PALI trades over the next 12 months.
$10.22 +605.0% upside Strong Buy
Current$1.45 Low$5.00 Median$8.00 High$25.00 9 analysts
$5.00$25.00
Analyst rating Strong Buy· 1.1/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
75°
Bullish
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 8 neutral · avg impact 3.8/10.
NEUTRAL8-K5/10
Palisade Bio reported Q2 2026 results in line with Street consensus (EPS -$0.05 vs -$0.05 est), with
Aug 11, 2026
NEUTRALCLUSTER2/10
A small insider cluster at Palisade Bio (PALI) shows mixed activity: Director Baltera purchased ~$19
Jul 10, 2026
NEUTRALCLUSTER3/10
Insider trading cluster at PALISADE BIO shows CEO/CFO John David Finley selling $303K in open-market
Jul 8, 2026
NEUTRAL8-K4/10
Palisade Bio filed an 8-K reporting its 2026 annual meeting results, including stockholder approval
Jun 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: PALI — 78.2% short (1.0M / 1.3M)
Short: 987,074 | Exempt: 100 | TRF Vol: 1,262,663 | Short Ratio: 78.2% | Off-exchange volume (dark pool + OTC)
Sep 29, 2026
short_volume
Short Volume: PALI — 61.5% short (0.7M / 1.1M)
Short: 682,197 | Exempt: 4,648 | TRF Vol: 1,109,116 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
other
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn’s disease
Sep 24, 2026
short_volume
Short Volume: PALI — 62.8% short (1.0M / 1.6M)
Short: 1,031,444 | Exempt: 10 | TRF Vol: 1,643,183 | Short Ratio: 62.8% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
other
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.06 | $-0.07–$-0.05 | 83.8% | +0.0% | 1↑ 5↓ | $0.0B | 7 |
| Next Q | $-0.07 | $-0.09–$-0.05 | — | +0.0% | 2↑ 4↓ | $0.0B | 7 |
| Current FY | $-0.23 | $-0.25–$-0.20 | 24.8% | +0.0% | 2↑ 5↓ | $0.0B | 7 |
| Next FY | $-0.28 | $-0.40–$-0.20 | -24.0% | +0.0% | 1↑ 5↓ | $0.0B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.061 | — |
| 7d ago | $-0.061 | — |
| 30d ago | $-0.061 | — |
| 60d ago | $-0.061 | — |
| 90d ago | $-0.061 | — |
Institutional ownership
Which big funds own PALI (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $189.0M total value (90,406,787 shares) as of 2026-Q2. Top holders: AMERIPRISE, Jupiter, BlackRock,. Net buying activity: 16 institutions added/increased vs 9 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| AMERIPRISE FINANCIAL INC | 11,081,434 | $23.2M | 12.3% | ADD +27.2% |
| Jupiter Topco LLC | 10,689,452 | $22.4M | 11.8% | — |
| BlackRock, Inc. | 10,436,760 | $21.8M | 11.5% | DOUBLED +456.2% |
| RA CAPITAL MANAGEMENT, L.P. | 7,124,116 | $14.9M | 7.9% | NEW |
| FRANKLIN RESOURCES INC | 5,785,189 | $12.1M | 6.4% | NEW |
| Point72 Asset Management, L.P. | 5,253,403 | $11.0M | 5.8% | DOUBLED +1175.8% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4,500,000 | $9.4M | 5.0% | NEW |
| GEODE CAPITAL MANAGEMENT, LLC | 3,760,485 | $7.9M | 4.2% | DOUBLED +143.2% |
| WELLINGTON MANAGEMENT GROUP LLP | 3,703,936 | $7.7M | 4.1% | ADD +27.5% |
| GOLDMAN SACHS GROUP INC | 3,578,020 | $7.5M | 4.0% | TRIM -33.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| AMERIPRISE FINANCIAL INC | ADD | 8,711,385 | 11,081,434 | +27.2% | $23.2M |
| BlackRock, Inc. | DOUBLED | 1,876,340 | 10,436,760 | +456.2% | $21.8M |
| Point72 Asset Management, L.P. | DOUBLED | 411,772 | 5,253,403 | +1175.8% | $11.0M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 1,546,240 | 3,760,485 | +143.2% | $7.9M |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 2,904,911 | 3,703,936 | +27.5% | $7.7M |
| GOLDMAN SACHS GROUP INC | TRIM | 5,373,951 | 3,578,020 | -33.4% | $7.5M |
| STATE STREET CORP | DOUBLED | 636,197 | 2,475,648 | +289.1% | $5.2M |
| MORGAN STANLEY | TRIM | 4,551,533 | 2,474,069 | -45.6% | $5.2M |
| Aberdeen Group plc | DOUBLED | 662,900 | 1,910,205 | +188.2% | $4.0M |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 3,270,845 | 1,875,694 | -42.7% | $3.9M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 26 transactions. Net -$170.0K — $250.2K bought, $420.2K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Finley John David | CEO, CFO | GIFT | 88,400 | — | — |
| Jul 9, 2026 | Baltera Robert Jr. | Director | BUY | 25,000 | $1.96 | $48.9K |
| Jul 8, 2026 | Baltera Robert Jr. | Director | BUY | 20,000 | $1.99 | $39.8K |
| Jul 7, 2026 | Finley John David | CEO, CFO | SELL | 146,798 | $2.07 | $303.3K |
| Jul 7, 2026 | Finley John David | CEO, CFO | EXERCISE | 133 | $0.7000 | $93.10 |
| Jul 7, 2026 | Jones Mitchell Lawrence | Chief Medical Officer | SELL | 51,880 | $2.05 | $106.5K |
| Jul 7, 2026 | Baltera Robert Jr. | Director | BUY | 30,000 | $2.03 | $61.0K |
| Jul 6, 2026 | Finley John David | CEO, CFO | EXERCISE | 335,167 | — | — |
| Jul 6, 2026 | Jones Mitchell Lawrence | Chief Medical Officer | EXERCISE | 131,167 | — | — |
| Jul 6, 2026 | Baltera Robert Jr. | Director | BUY | 20,000 | $2.05 | $41.0K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PALI.
Shares short
30,267,286
Settlement Sep 15, 2026
Change vs prior
-2.0%
Semi-monthly cycle
Days to cover
13.8
At avg daily volume
Of shares outstanding
≈17.4%
Estimate — not % of float
All PALI filing & press-release reports (8)
- 8-K reportAug 11, 2026
- CLUSTER reportJul 10, 2026
- CLUSTER reportJul 8, 2026
- 8-K reportJun 11, 2026
- EFFECT reportMay 22, 2026
- S-3 reportMay 12, 2026
- DEFA14A reportApr 29, 2026
- 8-K reportApr 2, 2026